Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification

Cell Growth and Differentiation

Volumn 11, Issue 3, 2000, Pages 173-183

  Ram, Tracy G ^a   Schelling, Margaret E ^a   Hosick, Howard L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; PROTEIN P85; VIRUS VECTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETROVIRUS;

BREAST NEOPLASMS; CELL DIVISION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MITOGENS; NEUREGULIN-1; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

UNIDENTIFIED RETROVIRUS;

EID: 0034115478     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Coussens, L., Yang-Feng, T. L., Liao, Y-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Liberman, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
2. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S A. Isolation and characterization of ERBB3, a third member of the ERBB/ epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 9193-9197, 1989.
3. erbB-4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
4. Ullrich, A., and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 61: 203-212, 1990.
5. Carraway, K. L., and Cantley, L. C. A neu acquaintance of erbB3, and erbB4. A role for receptor heterodimerization in growth signaling. Cell, 78: 5-8, 1994.
6. erbB-2. Science (Washington DC), 256: 1205-1210, 1992.
7. Carraway, K. L., Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem., 269: 14303-14306, 1994.
8. erbB-4. Nature (Lond.), 366: 473-475, 1993.
9. Goldman, R., Ben Levy, R., Peles, E., and Yarden, Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29: 11024-11028, 1990.
10. neu protein and EGF receptor modulates EGF receptor function. Cell, 61: 1339-1347, 1990.
11. Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., and Carraway, K. L., III. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 269: 14661-14665, 1994.
12. Kita, Y. A., Barff, J., Duanzhi, W., Luo, Y., Wen, D., Brankow, D., Hu, S., Liu, N., Prigent, S. A., Gullick, W. J., and Nicolson, M. NDF/heregulin stimulates the phosphorylation of Her3/erbB3. FEBS Lett., 349: 139-143, 1994.
13. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
14. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ulirich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
15. Kraus, M. H., Popescu, N. C., Amsbaugh, S, C., and King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6: 605-610, 1987.
16. Hollywood, D. P., and Hurst, H. C. A novel transcription factor, OB2-1, is required for overexpression of proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J., 12: 2369-2375, 1993.
17. Varley, J. M., Swallow, J. E., Brammer, W. J., Whittaker, J. L., and Walker, R. A. Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlates with poor short-term prognosis. Oncogene, 1: 423-430, 1987.
18. Zhou, D., Battifora, H., Yokota, J., Yamamoto, T., and Cline, M. J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res., 47: 6123-6125, 1987.
19. Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., and Hynes, N. E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48: 1238-1243, 1988.
20. Kraus, M. H., Fedi, P., Starks, V., Muraro, R., and Aaronson, S. A. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc. Natl. Acad. Sci. USA, 90: 2900-2904, 1993.
21. Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Di Fiore, P. P., and Kraus, M. H. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene, 10: 1813-1821, 1995.
22. erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent mammary carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ., 7: 551-561, 1996.
23. Siegel, P. M., Ryan, E. D., Cardiff, R. D., and Muller, W. J. Elevated expression of activated forms of neu/erbB-2 and erbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J., 18: 2149-2164.
24. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH 3T3 cells. Science (Washington DC), 237: 178-182, 1987.
25. erbB-2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
26. Di Marco, E., Pierce, J. H., Knicley, C. L., and Di Fiore, P. P. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of rat neu gene. Mol. Cell. Biol., 10: 3247-3252, 1990.
27. Pierce, J. H., Amstein, P., DiMarco, E., Artrip, J., Kraus, M. H., Lonardo, F., Di Fiore, P. P., and Aaronson, S. A. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene, 6: 1189-1194, 1991.
28. Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9: 2109-2123, 1994.
29. Bargmann, C. I., Hung, M-C., and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of pI85. Cell, 45: 649-657, 1986.
30. Lemoine, N. R., Staddon, S., Dickson, C., Bames, D. M., and Gullick, W. J. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene, 5: 237-239, 1990.
31. erbB-2 is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2. Oncogene, 5: 879-883, 1990.
32. Di Fiore, P. P., Segatto, O., Lonardo, F., Fazioli, F., Pierce, J. H., and Aaronson, S. A. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol. Cell. Biol., 10: 2749-2756, 1990.
33. Lonardo, F., Di Marco, E., King, C. R., Pierce, J. H., Segatto, O., Aaronson, S. A., and Di Fiore, P. P. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol., 2: 992-1003, 1990.
34. Soltoff, S. P., Carraway, K. L., III, Prigent, S. A., Gullick, W. G., and Cantley, L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol., 14: 3550-3558, 1994.
35. Kim, H-H., Slerke, S. L., and Koland, J. G. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J. Biol. Chem., 269: 24747-24755, 1994.
36. Kashles, O., Yarden, Y., Fischer, R., Ullrich, A., and Schlessinger, J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol. Cell. Biol., 11: 1454-1463, 1991.
37. Ueno, H., Colbert, H., Escobedo, J. A., and Williams, L. T. Inhibition of PDGF receptor signal transduction by coexpression of a truncated receptor. Science (Washington DC), 252: 844-848, 1991.
38. Amaya, E., Muscl, T. J., and Kirshner, M. W. Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell, 66: 257-270, 1991.
39. Jones, F. E., and Stern, D. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene, 18: 3481-3490, 1999.
40. Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., and Yarden, Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J., 15: 254-264, 1996.
41. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., and Yarden, Y. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15: 2452-2467, 1996.
42. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol., 16: 5276-5287, 1996.
43. Band, V., Zajchowski, D., Swisshelm, K., Trask, D., Kulesa, B., Cohen, C., Connolly, J., and Sager, R. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res., 50: 7351-7357, 1990.
44. Band, V., and Sager, R. Tumor progression in breast cancer. In: J. S. Rhim and A. Dritschilo (eds.), Neoplastic Transformation in Human Cell Culture, pp. 169-178. Clifton, NJ: Humana Press, 1991.
45. erbB-2. Mol. Carcinog., 15: 227-238, 1996.
46. Hu, P., Margolis, B., Skoinik, Y., Lammers, R., Ullrich, A., and Schlessinger, J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol. Cell. Biol., 12: 981-990, 1992.
47. Backer, J., Myers, M. G., Shoelson, S. E., Chin, D. J., Sun, X-S., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schiessinger, J., and White, M. F. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J., 11: 3469-3479, 1992.
48. Yamamoto, K., Lapetina, E. G., and Moxham, C. P. Insulin like growth factor-I induces limited association of phosphatidylinositol 3-kinase to its receptor. Endocrinology, 130: 1490-1498, 1992.
49. Mehta, R. R., Graves, J. M., Hart, G. D., Shilkaitis, A., and Das Gupta, T. K. Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res. Treat., 25: 65-71, 1993.
50. Band, V., Zajchowski, D., Stenman, G., Morton, C. C., Kulesa, V., Connolly, J., and Sager, R. A newly established metastatic breast tumor cell line with integrated amplified copies of erbB2 and double minute chromosomes. Genes Chromosomes Cancer, 1: 48-58, 1989.
51. Ram, T. G., Hosick, H. L., and Ethier, S. P. Heregulin-β is especially potent in activating phosphatidylinositol 3-kinase in non-transformed human mammary epithelial cells. J. Cell. Physiol., in press, 2000.
52. Ram, T. G., Kokeny, K. E., Dilts, C. A., and Ethier, S. P. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells. J. Cell Physiol., 163: 589-596, 1995.